RankAlpha logo
Back to Rankings

PTCT

PTC TherapeuticsB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The post-earnings bull case is that Sephience launch momentum is proving stronger and broader than expected, the Q1 beat justified a guidance raise, and votoplam plus the disclosed $50M Novartis milestone add pipeline-backed cash support. PTCT also traded materially above the 2026-05-07 anchor after the release, consistent with a favorable initial market read.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.4.
What can break
Emflaza revenue fell year over year due to continued generic erosion, offsetting part of the broader portfolio strength.
Momentum
58
Value
70
Sentiment
52
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $72.00 · Bull $82.00 · Bear $54.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $87.57
Why
Momentum58 · Δ7d +7.6
Value70 · Δ7d -0.4
Sentiment52 · Δ7d -3.8
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
58
34% active weight
Current posture
7d trendImproving
Δ7d
+7.6
Δ21d
+17.7
Value
70
32% active weight
Current posture
7d trendFlat
Δ7d
-0.4
Δ21d
+0.4
Sentiment
52
33% active weight
Current posture
7d trendSoftening
Δ7d
-3.8
Δ21d
+11.3
Why this grade

Composite grade B. Momentum 57.6 / Value 70.2 / Sentiment 52.2

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$6.12B
Beta
0.48
Shares Out
80.29M
P/E (TTM)
9.0
P/S (TTM)
3.46
P/FCF (TTM)
8.74
Rev YoY
+7.2%
EPS YoY
+113.2%
Gross Margin
+96.8%
Op Margin
+49.2%
Net Debt
$1.25B
Current Ratio
2.32
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology